Physician profile
Jonathan D Edwards
NPI 1720097298
$1,024.11
in general payments reported to CMS, 2019-2025
24 companies · $93.80 in 2025
The $93.80 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.30 · 2020: $285 · 2021: $151 · 2022: $144 · 2023: $87.16 · 2024: $163 · 2025: $93.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $343.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $150.00 | 2020 | |
| Abbvie INC. | $107.05 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $86.88 | 2020-2024 | Hetlioz, Fanapt |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.99 | 2020-2024 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $63.58 | 2022-2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.91 | 2021-2023 | Xifaxan |
| Mylan Specialty L.P. | $52.77 | 2021-2024 | Yupelri |
| Amgen INC. | $49.48 | 2021-2022 | |
| Novo Nordisk INC | $45.36 | 2021-2024 | Wegovy, Rybelsus, Ozempic |
| Astellas Pharma US INC | $44.76 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $36.26 | 2022 | |
| Amneal Pharmaceuticals LLC | $33.18 | 2024 | Rytary |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31.58 | 2020 | |
| Pharmacyclics LLC, An Abbvie Company | $29.69 | 2023 | Epkinly |
| Novartis Pharmaceuticals Corporation | $22.83 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $19.42 | 2020 | |
| Boston Scientific Corporation | $18.32 | 2025 | General - Therapies |
| Ironshore Pharmaceuticals INC. | $18.14 | 2019 | |
| Biogen, INC. | $16.39 | 2021 | |
| Indivior INC. | $15.04 | 2020 | |
| Janssen Pharmaceuticals, INC | $13.57 | 2019 | |
| Dexcom, INC. | $13.26 | 2023 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $12.98 | 2020 | |
| Merck Sharp & Dohme LLC | $12.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.